PREDICTING THE RISK OF RELAPSE WITH IMMUNOSCORE®

(0)
PREDICTING THE RISK OF RELAPSE WITH IMMUNOSCORE®
Immuno-oncology Diagnostics
Jun 01, 2021

Colorectal cancer is responsible for approximately 1 in 6 of all cancer diagnoses in Singaporean men and 1 in 7 in Singaporean women, with Chinese men and women being most at risk[1].

Veracyte logo

Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our immuno-oncology diagnostic products and services are used to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

IMMUNOSCORE® provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration in human tumors and has been shown to predict patient outcome: response to therapies in several indications. IMMUNOSCORE® can guide treatment decision-making by giving healthcare professionals a clear and actionable measurement of how an individual patient’s immune system is responding to their cancer. IMMUNOSCORE® is available for a growing number of indications.

HOW IMMUNOSCORE® FOR COLON CANCER WORKS

By providing an accurate measurement of T lymphocyte infiltration into the tumor, Immunoscore® gives healthcare providers insight into the risk of relapse.

A low Immunoscore® means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, a high Immunoscore® means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.

For example, a study has shown that Immunoscore® combined with imaging was able to identify very good responders to neoadjuvant treatment. In the "Watch and Wait" cohort, 100% success was observed in patients with Immunoscore High.

 

 

 

INTERESTED IN ORDERING A TEST?

Contact enquiry@sagehealthcare.sg for more information!